Patents by Inventor Alexander J. Nichols
Alexander J. Nichols has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240358860Abstract: Compounds, systems, and methods are provided for the design and assembly of a non-invasive, analyte sensing dressing. The dressing can be therapeutic. The dressing includes a sensor and a matrix. The sensor is capable of detecting analytes such as molecular oxygen, carbon dioxide, nitric oxides, dissolved analytes in plasma, and hydrogen ions. The matrix is at least partially permeable to the analyte. The device emits a detectable signal when the sensor is excited in the presence of the analyte. In one version of the dressing, the sensor includes a meso-unsubstituted metallated porphyrin that is sensitive towards oxygen. The metallated porphyrin can be excited when illuminated at a first wavelength, followed by emission of phosphorescence at a second wavelength whose intensity can be used as an indicator for oxygen concentration.Type: ApplicationFiled: July 11, 2024Publication date: October 31, 2024Applicant: The General Hospital CorporationInventors: Conor L. Evans, Gabriela Apiou, Alexander J. Nichols, Emmanouil Rousakis, Zongxi Li
-
Patent number: 12059481Abstract: Compounds, systems, and methods are provided for the design and assembly of a non-invasive, analyte sensing dressing. The dressing can be therapeutic. The dressing includes a sensor and a matrix. The sensor is capable of detecting analytes such as molecular oxygen, carbon dioxide, nitric oxides, dissolved analytes in plasma, and hydrogen ions. The matrix is at least partially permeable to the analyte. The device emits a detectable signal when the sensor is excited in the presence of the analyte. In one version of the dressing, the sensor includes a meso-unsubstituted metallated porphyrin that is sensitive towards oxygen. The metallated porphyrin can be excited when illuminated at a first wavelength, followed by emission of phosphorescence at a second wavelength whose intensity can be used as an indicator for oxygen concentration.Type: GrantFiled: January 25, 2022Date of Patent: August 13, 2024Assignee: The General Hospital CorporationInventors: Conor L. Evans, Gabriela Apiou, Alexander J. Nichols, Emmanouil Rousakis, Zongxi Li
-
Publication number: 20240158493Abstract: Provided herein are antigen-binding protein constructs and antibodies and uses of the same.Type: ApplicationFiled: April 5, 2022Publication date: May 16, 2024Applicant: Mythic Therapeutics, Inc.Inventors: Alexander J. Nichols, Brian P. Fiske, Nimish Gera
-
Publication number: 20240141065Abstract: Provided herein are antibodies and uses of the same.Type: ApplicationFiled: February 3, 2022Publication date: May 2, 2024Applicant: Mythic Therapeutics, Inc.Inventors: Brian P. Fiske, Nimish Gera, Alexander J. Nichols
-
Publication number: 20240101688Abstract: Provided herein are antibodies and uses of the same.Type: ApplicationFiled: November 15, 2023Publication date: March 28, 2024Applicant: Mythic Therapeutics, Inc.Inventors: Brian P. Fiske, Nimish Gera, Alexander J. Nichols
-
Publication number: 20220348679Abstract: Provided herein are antigen-binding protein constructs and uses of the same.Type: ApplicationFiled: October 2, 2020Publication date: November 3, 2022Applicant: Mythic Therapeutics, Inc.Inventors: Alexander J. Nichols, Brian Fiske, Nimish Gera
-
Publication number: 20220324969Abstract: Provided herein are antigen-binding protein constructs capable of specifically binding CD33 or an epitope of CD33 presented on the surface of a target mammalian cell, wherein said antigen binding is pH-dependent. Provided are also uses of said antigen-binding protein constructs.Type: ApplicationFiled: June 5, 2020Publication date: October 13, 2022Applicant: Mythic Therapeutics, Inc.Inventors: Alexander J. Nichols, Brian P. Fiske, Nimish Gera
-
Publication number: 20220313845Abstract: Provided herein are antigen-binding protein constructs capable of specifically binding DLL3 or an epitope of DLL3 presented on the surface of a target mammalian cell, wherein said antigen binding is pH-dependent. Provided are also uses of said antigen-binding protein constructs.Type: ApplicationFiled: June 5, 2020Publication date: October 6, 2022Applicant: Mythic Therapeutics, Inc.Inventors: Alexander J. Nichols, Brian P. Fiske, Nimish Gera
-
Publication number: 20220306751Abstract: Provided herein are antigen-binding protein constructs and uses of the same.Type: ApplicationFiled: September 11, 2020Publication date: September 29, 2022Applicant: Mythic Therapeutics, Inc.Inventors: Alexander J. Nichols, Brian P. Fiske, Nimish Gera
-
Publication number: 20220298260Abstract: Provided herein are antigen-binding protein constructs capable of specifically binding FOLR1 or an epitope of FOLR1 presented on the surface of a target mammalian cell, wherein said antigen binding is pH-dependent. Provided are also uses of said antigen-binding protein constructs.Type: ApplicationFiled: June 5, 2020Publication date: September 22, 2022Applicant: Mythic Therapeutics, Inc.Inventors: Alexander J. Nichols, Brian P. Fiske, Nimish Gera
-
Publication number: 20220288219Abstract: Provided herein are antigen-binding protein constructs capable of specifically binding CD22 or an epitope of CD22 presented on the surface of a target mammalian cell, wherein said antigen binding is pH-dependent. Provided are also uses of said antigen-binding protein constructs.Type: ApplicationFiled: July 8, 2020Publication date: September 15, 2022Applicant: Mythic Therapeutics, Inc.Inventors: Alexander J. Nichols, Brian P. Fiske, Nimish Gera
-
Publication number: 20220281984Abstract: Provided herein are antigen-binding protein constructs capable of specifically binding MET or an epitope of MET presented on surface of a target mammalian cell, wherein said antigen binding is pH-dependent. Provided are also uses of said antigen-binding protein constructs.Type: ApplicationFiled: July 30, 2020Publication date: September 8, 2022Applicant: Mythic Therapeutics, Inc.Inventors: Alexander J. Nichols, Brian P. Fiske, Nimish Gera
-
Publication number: 20220257797Abstract: Compounds, systems, and methods are provided for the design and assembly of a non-invasive, analyte sensing dressing. The dressing can be therapeutic. The dressing includes a sensor and a matrix. The sensor is capable of detecting analytes such as molecular oxygen, carbon dioxide, nitric oxides, dissolved analytes in plasma, and hydrogen ions. The matrix is at least partially permeable to the analyte. The device emits a detectable signal when the sensor is excited in the presence of the analyte. In one version of the dressing, the sensor includes a meso-unsubstituted metallated porphyrin that is sensitive towards oxygen. The metallated porphyrin can be excited when illuminated at a first wavelength, followed by emission of phosphorescence at a second wavelength whose intensity can be used as an indicator for oxygen concentration.Type: ApplicationFiled: January 25, 2022Publication date: August 18, 2022Inventors: Conor L. Evans, Gabriela Apiou, Alexander J. Nichols, Emmanouil Rousakis, Zongxi Li
-
Patent number: 11253613Abstract: Compounds, systems, and methods are provided for the design and assembly of a non-invasive, analyte sensing dressing that includes a sensor and a matrix. The sensor is capable of detecting analytes such as molecular oxygen. The matrix is at least partially permeable to the analyte. In one version of the dressing, the sensor includes a meso-unsubstituted metallated porphyrin that is sensitive towards oxygen. The metallated porphyrin can be excited when illuminated at a first wavelength, followed by emission of phosphorescence at a second wavelength whose intensity can be used as an indicator for oxygen concentration. The metallated porphyrin can be prepared from a phosphorescent meso-unsubstituted porphyrin having the Formula (I): wherein M is a metal, wherein each R is independently an atom or a group of atoms, and wherein at least one R is —O(C)OR?, wherein R? is optionally substituted alkyl.Type: GrantFiled: February 11, 2020Date of Patent: February 22, 2022Assignee: The General Hospital CorporationInventors: Conor L. Evans, Gabriela Apiou, Alexander J. Nichols, Emmanouil Rousakis, Zongxi Li
-
Patent number: 10905780Abstract: Compounds, systems, and methods are provided for the design and assembly of a non-invasive, analyte sensing dressing. The dressing can be therapeutic. The dressing includes a sensor and a matrix. The sensor is capable of detecting analytes such as molecular oxygen, carbon dioxide, nitric oxides, dissolved analytes in plasma, and hydrogen ions. The matrix is at least partially permeable to the analyte. The device emits a detectable signal when the sensor is excited in the presence of the analyte. In one version of the dressing, the sensor includes a meso-unsubstituted metallated porphyrin that is sensitive towards oxygen. The metallated porphyrin can be excited when illuminated at a first wavelength, followed by emission of phosphorescence at a second wavelength whose intensity can be used as an indicator for oxygen concentration.Type: GrantFiled: August 3, 2018Date of Patent: February 2, 2021Assignee: The General Hospital CorporationInventors: Conor L. Evans, Gabriela Apiou, Alexander J. Nichols, Emmanouil Rousakis, Zongxi Li
-
Publication number: 20200171172Abstract: Compounds, systems, and methods are provided for the design and assembly of a non-invasive, analyte sensing dressing. The dressing can be therapeutic. The dressing includes a sensor and a matrix. The sensor is capable of detecting analytes such as molecular oxygen, carbon dioxide, nitric oxides, dissolved analytes in plasma, and hydrogen ions. The matrix is at least partially permeable to the analyte. The device emits a detectable signal when the sensor is excited in the presence of the analyte. In one version of the dressing, the sensor includes a meso-unsubstituted metallated porphyrin that is sensitive towards oxygen. The metallated porphyrin can be excited when illuminated at a first wavelength, followed by emission of phosphorescence at a second wavelength whose intensity can be used as an indicator for oxygen concentration.Type: ApplicationFiled: February 11, 2020Publication date: June 4, 2020Inventors: Conor L. Evans, Gabriela Apiou, Alexander J. Nichols, Emmanouil Rousakis, Zongxi Li
-
Patent number: 10524707Abstract: In one aspect, the present disclosure provides a system A system, including a light source, a detector, and a controller in electrical communication with the light source and the detector. The controller is configured to execute a program stored in the controller to trigger the light source to emit a first pulse of light having a first pulse duration for illumination of a target, actuate the detector after a first delay time following emission of the first pulse of light to begin detecting a first signal from the target for a first detection time, and repeat the steps of triggering the light source and actuating the detector at least once, varying for each repetition at least one of the first pulse duration, the first delay time, and the first detection time.Type: GrantFiled: February 2, 2015Date of Patent: January 7, 2020Assignee: The General Hospital CorporationInventors: Zongxi Li, Conor L. Evans, Alexander J. Nichols
-
Publication number: 20180344878Abstract: Compounds, systems, and methods are provided for the design and assembly of a non-invasive, analyte sensing dressing. The dressing can be therapeutic. The dressing includes a sensor and a matrix. The sensor is capable of detecting analytes such as molecular oxygen, carbon dioxide, nitric oxides, dissolved analytes in plasma, and hydrogen ions. The matrix is at least partially permeable to the analyte. The device emits a detectable signal when the sensor is excited in the presence of the analyte. In one version of the dressing, the sensor includes a meso-unsubstituted metallated porphyrin that is sensitive towards oxygen. The metallated porphyrin can be excited when illuminated at a first wavelength, followed by emission of phosphorescence at a second wavelength whose intensity can be used as an indicator for oxygen concentration.Type: ApplicationFiled: August 3, 2018Publication date: December 6, 2018Inventors: Conor L. Evans, Gabriela Apiou, Alexander J. Nichols, Emmanouil Rousakis, Zongxi Li
-
Patent number: 10039842Abstract: Compounds, systems, and methods are provided for the design and assembly of a non-invasive, analyte sensing dressing. The dressing includes a sensor and a matrix. The sensor is capable of detecting analytes such as molecular oxygen, carbon dioxide, nitric oxides, dissolved analytes in plasma, and hydrogen ions. The device emits a detectable signal when the sensor is excited in the presence of the analyte. In one version of the dressing, the sensor includes a meso-unsubstituted metallated porphyrin that is sensitive towards oxygen. The metallated porphyrin can be excited when illuminated at a first wavelength, followed by emission of phosphorescence at a second wavelength whose intensity can be used as an indicator for oxygen concentration. The porphyrin can have the Formula (II): wherein R1 includes a moiety selected from the group consisting of alkynl groups, triazolyl groups, alkylglutamate groups, and a pair of alkylglutamate groups.Type: GrantFiled: August 23, 2017Date of Patent: August 7, 2018Assignee: The General Hospital CorporationInventors: Conor L. Evans, Gabriela Apiou, Alexander J. Nichols, Emmanouil Rousakis, Zongxi Li
-
Patent number: 10016164Abstract: A system and method are provided for the design and assembly of a device including a sensor capable and a compatible matrix material incorporated into a dressing. The sensor is capable of detecting analytes such as molecular oxygen, carbon dioxide, nitric oxides, dissolved analytes in plasma, and hydrogen ions, and the matrix is at least partially permeable to the analyte. The device emits a detectable signal when the sensor is excited in the presence of the analyte.Type: GrantFiled: July 10, 2013Date of Patent: July 10, 2018Assignee: The General Hospital CorporationInventors: Conor L. Evans, Gabriela Apiou, Reginald Birngruber, Alexander J. Nichols, Emmanouil Rousakis, Zongxi Li